7 medtech stories we missed this week: Sept. 22, 2017
[Image from unsplash.com]From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, clinic and directly to patients without a prescription. The MediClear PreOp is a breathable, transparent, self-adhesive, silicone barrier film-drape that can conform to a patient’s skin at a planned incision or insertion site. The film-drape helps protect the patient from bacteria, yeast and viruses. It can be applied by the patient or by clinicians at a consultation prior to surgical procedures. It is then removed immediately before surgery by a clinician in the operating room under sterile conditions. 2. ManaMed launches PlasmaFlow deep vein thrombosis prevention system ManaMed has launched the first FDA-approved digital and tubeless deep vein thrombosis prevention device, according to a Sept. 21 press release. The deep vein thrombosis prevention device, known as PlasmaFlow, is now available to medical practitioners in the U.S. PlasmaFlow is portable and tubeless with multiple pressure functions. It features a one-button operation, soft cuffs made of a high-grade medical material, 10 hours of rechargeable battery life and two LCD screen with a timer and pressure. I...
CONCLUSION: In LAO patients, directly proceeding EVT following IVT may not be hesitated. In addition, while LAO patients with incomplete IV-tPA treatment responses result in transient improvement of neurological symptoms but later reversed, EVT may be a potential rescue therapy in carefully selected patients. PMID: 30315557 [PubMed - in process]
Publication date: 1 January 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 173Author(s): Li-Ying Huang, Ming-Chien Yang, Hui-Ming Tsou, Ting-Yu LiuAbstractTo solve the thrombosis and restenosis problem in cardiovascular stent implantation for cardiovascular artery disease, chondroitin 6-sulfate (ChS) with heparin (HEP) have been used as drug carrier layers and alternatively covalently bonded on gold (Au)-dimercaptosuccinic acid (DMSA)-thiolized cardiovascular metallic (SUS316 L stainless steel, SS) stents. Sirolimus, a model drug, was encapsulated in the ChS-HEP alternative layers. The behavior of the dr...
Liver International,Volume 0, Issue ja, -Not available-.
ConclusionAspirin represents a safe and effective choice for extended VTE prophylactic in low-risk patients, as it is effective (for a mean duration of 1 month), safe, associated with high compliance rates, and is less expensive than other options.
Acta Anaesthesiologica Scandinavica, EarlyView.
Publication date: Available online 25 September 2018Source: Indian Heart JournalAuthor(s): Fidel Manuel Caceres-Loriga
Authors: Du F, Zhou J Abstract Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide. Clinically, CAD can be potentially managed through surgical artery bypass. However, due to the highly invasive nature, surgical intervention has been gradually replaced by percutaneous transluminal coronary angioplasty and recently by percutaneous coronary revascularization using metallic stents. However, the permanent presence of metallic scaffolds inevitably impairs arterial physiology and may induce a variety of adverse effects, such as inflammation, restenosis, thrombosis, and neoatheroscleros...
Publication date: Available online 13 October 2018Source: Neurología (English Edition)Author(s): S. Quintas, I. Palmí Cortés, G. Zapata-Wainberg, R. López Ruiz, J. Vivancos
Authors: Yoon SY, Lee MY, Yoon J, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Hong DS, Won JH Abstract Background: Pancreatic cancer is among the most common malignancies associated with venous thromboembolism (VTE). Asian patients are known to have a lower incidence of VTE compared to Caucasian patients. However, few studies have investigated the incidence of VTE in Asian patients with pancreatic cancer. Methods: This retrospective review of medical records was performed on 505 patients with histopathologically proven advanced stage pancreatic cancer, from January 2006 to December ...
Conclusionsand recommendations: Based on the data and the literature revision, skin or skeletal traction for patients with proximal femoral fractures should be discouraged as standard practice. This is supported widely in the internationally literature, and consideration of knowledge translation strategies should be made to refine current practice in these settings.
More News: Angioplasty | Austria Health | Baloon Angioplasty | Belgium Health | Carotid Angioplasty | France Health | Germany Health | Hospitals | Laboratory Medicine | Medical Devices | Men | Nanotechnology | Netherlands Health | PET Scan | Portugal Health | Skin | Spain Health | Study | Thrombosis | Ultrasound